Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wurtz

Showing results (681-690 of 725) with videos related to

Pageof 73
Sort By:
Cancer Research|February 15, 2024
ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular ContextsBomiao Hu, Marc Wiesehöfer, Fernando J de Miguel, et al.
Cancer Discovery|March 12, 2021
Genetic Determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response <i>In Vivo</i>Giorgia Foggetti, Chuan Li, Hongchen Cai, et al.
JCI Insight|August 26, 2025
B3GALT6 mutations lead to compromised connective tissue biomechanics in Ehlers-Danlos syndromeRoméo Milan Diana, Benjamin Jolivet, Jean-Baptiste Vincourt, et al.
ACS Pharmacology & Translational Science|October 21, 2022
Molecular Mechanisms of Desensitization Underlying the Differential Effects of Formyl Peptide Receptor 2 Agonists on Cardiac Structure-Function Post Myocardial InfarctionJohn Lupisella, Stéphane St-Onge, Marilyn Carrier, et al.
Journal of Medicinal Chemistry|July 26, 2016
Discovery of a Highly Potent, Selective, and Orally Bioavailable Macrocyclic Inhibitor of Blood Coagulation Factor VIIa-Tissue Factor ComplexXiaojun Zhang, Peter W Glunz, James A Johnson, et al.
ACS Medicinal Chemistry Letters|January 8, 2019
Potent Triazolopyridine Myeloperoxidase InhibitorsNicholas R Wurtz, Andrew Viet, Scott A Shaw, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 6, 2025
Quantitative Protein Expression of Antibody-Drug Conjugate Targets in EGFR Mutated and Wild-Type Non-Small Cell Lung CancerIoannis P Trontzas, Mengni He, Anna Wurtz, et al.
Journal of Medicinal Chemistry|May 15, 2020
Discovery of BMS-986235/LAR-1219: A Potent Formyl Peptide Receptor 2 (FPR2) Selective Agonist for the Prevention of Heart FailureYoshikazu Asahina, Nicholas R Wurtz, Kazuto Arakawa, et al.
EMBO Molecular Medicine|April 3, 2025
Formyl-peptide receptor type 2 activation mitigates heart and lung damage in inflammatory arthritisAndreas Margraf, Jianmin Chen, Marilena Christoforou, et al.
Journal of AOAC International|September 18, 1999
IUPAC collaborative trial study of a method to detect genetically modified soy beans and maize in dried powderM Lipp, P Brodmann, K Pietsch, et al.
Pageof 73

Showing results (681-690 of 725) with videos related to

Sort By:
Pageof 73
Cancer Research|February 15, 2024
ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular ContextsBomiao Hu, Marc Wiesehöfer, Fernando J de Miguel, et al.
Cancer Discovery|March 12, 2021
Genetic Determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response <i>In Vivo</i>Giorgia Foggetti, Chuan Li, Hongchen Cai, et al.
JCI Insight|August 26, 2025
B3GALT6 mutations lead to compromised connective tissue biomechanics in Ehlers-Danlos syndromeRoméo Milan Diana, Benjamin Jolivet, Jean-Baptiste Vincourt, et al.
ACS Pharmacology & Translational Science|October 21, 2022
Molecular Mechanisms of Desensitization Underlying the Differential Effects of Formyl Peptide Receptor 2 Agonists on Cardiac Structure-Function Post Myocardial InfarctionJohn Lupisella, Stéphane St-Onge, Marilyn Carrier, et al.
Journal of Medicinal Chemistry|July 26, 2016
Discovery of a Highly Potent, Selective, and Orally Bioavailable Macrocyclic Inhibitor of Blood Coagulation Factor VIIa-Tissue Factor ComplexXiaojun Zhang, Peter W Glunz, James A Johnson, et al.
ACS Medicinal Chemistry Letters|January 8, 2019
Potent Triazolopyridine Myeloperoxidase InhibitorsNicholas R Wurtz, Andrew Viet, Scott A Shaw, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 6, 2025
Quantitative Protein Expression of Antibody-Drug Conjugate Targets in EGFR Mutated and Wild-Type Non-Small Cell Lung CancerIoannis P Trontzas, Mengni He, Anna Wurtz, et al.
Journal of Medicinal Chemistry|May 15, 2020
Discovery of BMS-986235/LAR-1219: A Potent Formyl Peptide Receptor 2 (FPR2) Selective Agonist for the Prevention of Heart FailureYoshikazu Asahina, Nicholas R Wurtz, Kazuto Arakawa, et al.
EMBO Molecular Medicine|April 3, 2025
Formyl-peptide receptor type 2 activation mitigates heart and lung damage in inflammatory arthritisAndreas Margraf, Jianmin Chen, Marilena Christoforou, et al.
Journal of AOAC International|September 18, 1999
IUPAC collaborative trial study of a method to detect genetically modified soy beans and maize in dried powderM Lipp, P Brodmann, K Pietsch, et al.
Pageof 73